Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 1/20 | 0.41 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.41 |
| ▸ | KMO | O15229 | 2/20 | 0.41 |
| ▸ | DHODH | Q02127 | 2/20 | 0.41 |
| ▸ | FFAR2 | O15552 | 1/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.38 |
| ▸ | FABP4 | P15090 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | CA12 | O43570 | 1/20 | 0.38 |
| ▸ | CA1 | P00915 | 1/20 | 0.38 |
| ▸ | CA2 | P00918 | 1/20 | 0.38 |
| ▸ | CA7 | P43166 | 1/20 | 0.38 |
| ▸ | CA9 | Q16790 | 1/20 | 0.38 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.38 |
| ▸ | PFKFB3 | Q16875 | 1/20 | 0.37 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3753312 | 0.93 | ADORA2A (0.43) | ADORA2AADORA1KMODHODHNPSR1 | |
| SCHEMBL3747394 | 0.87 | KMO (0.39) | ADORA2AADORA1KMODHODHNPSR1 | |
| SCHEMBL8213830 | 0.82 | ADORA2A (0.39) | ADORA2AADORA1KMODHODH | |
| SCHEMBL3759883 | 0.82 | KMO (0.46) | KMODHODHNPSR1 | |
| SCHEMBL3750094 | 0.78 | ADORA2A (0.48) | ADORA2AADORA1DHODHPFKFB3ADORA3 | |
| SCHEMBL3752343 | 0.78 | GPBAR1 (0.36) | ADORA2AADORA1NPSR1LMNAADORA3 | |
| SCHEMBL3752748 | 0.78 | CTSA (0.38) | KMO | |
| SCHEMBL25459770 | 0.77 | LMNA (0.46) | KMOLMNA | |
| SCHEMBL8218304 | 0.75 | LMNA (0.43) | ADORA2AADORA1LMNAADORA3 | |
| SCHEMBL3752597 | 0.75 | ADORA2A (0.41) | ADORA2AADORA1KMODHODHNPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230150940-A1 | HSD17B13 INHIBITORS AND USES THEREOF | INIPHARM, INC. | 2023-05-18 | — | — | US | disclosed |
| US-20230150940-A1 | HSD17B13 INHIBITORS AND USES THEREOF | INIPHARM, INC. | 2023-05-18 | — | — | US | disclosed |
| WO-2021211974-A1 | HSD17B13 INHIBITORS AND USES THEREOF | INIPHARM, INC. (US) | 2021-10-21 | — | — | WO | disclosed |
| US-20100298221-A1 | 2-PHENOXY NICOTINE ACID DERIVATIVE AND USE THEREOF | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-11-25 | — | — | US | disclosed |
| US-20100298221-A1 | 2-PHENOXY NICOTINE ACID DERIVATIVE AND USE THEREOF | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-11-25 | — | — | US | disclosed |
| US-20100298221-A1 | 2-PHENOXY NICOTINE ACID DERIVATIVE AND USE THEREOF | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-11-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100298221-A1 | 2-PHENOXY NICOTINE ACID DERIVATIVE AND USE THEREOF | NAPRT, PNPO, FABP3 | ADORA2A 509/4885ADORA1 454/4885KMO 533/4885 |
| US-20230150940-A1 | HSD17B13 INHIBITORS AND USES THEREOF | HSD17B1, HSD17B3, HSD17B13 | ADORA2A 4678/4885ADORA1 4623/4885KMO 1170/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.